Skip to main content

Month: February 2026

IMCD reports EBITA of EUR 498 million in 2025

Rotterdam, The Netherlands (18 February 2026) – IMCD N.V. (“IMCD” or “Company”), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, today announces its full-year 2025 results. HIGHLIGHTS• Revenue at EUR 4,779 million (+5% on a constant currency basis)• Gross profit at EUR 1,194 million (+3% on a constant currency basis)• Operating EBITA at EUR 498 million (-3% on a constant currency basis)• Free cash flow up by 3% to EUR 465 million (2024: EUR 450 million)• Cash earnings per share at EUR 5.19 (2024: EUR 6.34)• Dividend proposal of EUR 1.81 in cash per share (2024: EUR 2.15)• Successful completion of 7 acquisitions across all our regions in 2025 Marcus Jordan, CEO: “After a good first quarter, the following quarters of 2025 were challenging amid macroeconomic...

Continue reading

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and demonstrated a favorable safety profile, including no liver safety concerns1Oral remibrutinib has potential to be first targeted therapy approved for CIndU, which affects estimated 29 million adults worldwide2,3Basel, February 18, 2026 – Novartis today announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU)1. The primary endpoint was met for the three most prevalent types of CIndU: symptomatic dermographism, cold urticaria and cholinergic urticaria, achieving significantly higher complete response rates versus placebo at Week 121. These data represent...

Continue reading

Hepsor AS consolidated unaudited interim report for Q4 2025 and twelve months

The Group’s consolidated revenue for the fourth quarter of 2025 amounted to 4.5 million euros (Q4 2024: 10.5 million euros), while the consolidated revenue for the reporting year was 35.4 million  euros (2024: 38.4 million euros). The Group recorded a net loss of  0.5 million euros for the fourth quarter (Q4 2024: net profit of 1.0 million euros), of which the net loss attributable to the owners of the parent company was 0.5 million  euros (Q4 2024: net profit of 1.0 million euros). The Group’s net profit for 2025 was 1.0 million euros (2024: 2.1 million euros). The net profit attributable to the owners of the parent company for the reporting year was 0.4 million euros (2024:  0.4 million euros). Compared with the previous year, the Group’s revenue and profitability in 2025 were affected by a decrease in the number of apartments handed...

Continue reading

Getty Realty Corp. Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) — Getty Realty Corp. (NYSE: GTY) (the “Company”), a net lease REIT focused on convenience and automotive retail real estate, today announced the pricing of an underwritten public offering of an aggregate of 4,000,000 shares of its common stock sold on a forward basis in connection with the forward sale agreements described below, for gross proceeds of approximately $131 million. The forward purchasers (or their affiliates) and the Company have also granted the underwriters of the offering a 30-day option to purchase up to an additional 600,000 shares of common stock. The offering is expected to close on February 19, 2026, subject to customary closing conditions. J.P. Morgan and Wells Fargo Securities acted as book-running managers for the offering. In connection with the offering of shares...

Continue reading

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflammation and disease, today announced the pricing of its follow-on offering of an aggregate of 2,477,292 units at a purchase price of $0.6055 per unit priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant, each to purchase one share of common stock. The warrant will have an exercise price of $0.6055 per share, will be exercisable upon shareholder approval, and will expire on the five-year anniversary from such date of shareholder approval. The shares of common...

Continue reading

Humanoid Global Announces Marketing Services

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – Vancouver, BC, Feb. 17, 2026 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, is pleased to announce  that it has entered into a marketing services agreement (the “Agreement”) with Investor Insights Systems Inc. (“IISI”) on February 12, 2026, whereby IISI will provide comprehensive digital marketing and advertising services for a term commencing on February 17, 2026 to May 15, 2026 (the “Initial Term”). Services provided by Investor Insights will be overseen by Mac Foster and he can be reached at 179 Shaw St. Toronto, Ontario,...

Continue reading

Purpose Investments Inc. Announces February 2026 Distributions

TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE) — Purpose Investments Inc. (“Purpose”) is pleased to announce distributions for the month of February 2026 for its open-end exchange-traded funds and closed-end funds (“the Funds”).                                                                        The ex-distribution date for all Open-End Funds is February 25, 2026. The ex-distribution date for all closed-end funds is February 27, 2026.Open-End Funds Ticker Symbol Distribution per share/unit Record Date Payable Date Distribution FrequencyApple (AAPL) Yield Shares Purpose ETF – ETF Units APLY $0.1667 02/25/2026 03/03/2026 MonthlyPurpose Couche-Tard (ATD) Yield Shares ETF – ETF Series ATDY $0.0650 02/25/2026 03/03/2026 MonthlyPurpose Canadian Financial Income Fund – ETF Series BNC $0.1225¹ 02/25/2026 03/03/2026 MonthlyPurpose...

Continue reading

CECO Environmental to Release Fourth Quarter Earnings and Host Conference Call on February 24

ADDISON, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced that it will report its fourth quarter 2025 financial results on February 24, 2026, premarket. The Company will also host its earnings call starting at 8:30 a.m. Eastern Time (7:30 a.m. CT). The Company’s financial results and presentation will be posted on its website at www.cecoenviro.com. The details for the webcast are: When: Tuesday, February 24 at 8:30 a.m. Eastern Time Where: https://edge.media-server.com/mmc/p/esi9fzv8 How: Live over the internet – Simply log on to the web at the address above Register to receive the dial-in info and a unique pin: https://register-conf.media-server.com/register/BIef187ad40fff4b6eaf15a109421408ae A...

Continue reading

Novo Resources Releases Updated Corporate Presentation

PERTH, Australia, Feb. 17, 2026 (GLOBE NEWSWIRE) — Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate presentation, now available on the Company’s website. The new presentation outlines Novo’s strategic priorities, exploration results, project advancements, and near-term catalysts. It offers investors a clear and current view of Novo’s evolving growth strategy and its portfolio of high-potential gold assets. “Our updated corporate presentation reflects the significant progress we’ve made across our exploration portfolio,” said Mr. Michael Spreadborough, Executive Co-Chairman and acting CEO of Novo Resources. “As we continue to unlock value across our projects, we remain focused on delivering disciplined growth and long-term value for shareholders.”The...

Continue reading

SHARC Energy Announces $2.0M Convertible Debenture Financing With 25% Greenshoe

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) would like to announce its intention to complete a non-brokered private placement of unsecured convertible debentures (each, a “Debenture”) with a principal amount of up to $2,000,000 (the “Offering”). The Offering will include an up to 25% over-allotment option, exercisable by the Company, which equates to an additional $500,000 (“Greenshoe”). If fully exercised, the total proceeds of the Offering will be gross proceeds of $2,500,000. The Debentures will bear interest at a rate of 8.0% per annum calculated annually and paid on maturity and will...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.